Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
MemeCore (M) fluctuated 34.5% in 24 hours: Network hard fork triggered a 40% surge followed by a strong pullback

MemeCore (M) fluctuated 34.5% in 24 hours: Network hard fork triggered a 40% surge followed by a strong pullback

Bitget PulseBitget Pulse2026/03/26 22:03
Show original
By:Bitget Pulse

Volatility Summary

M rebounded from a low of $1.8877 in the past 24 hours to a high of $2.5385, and is currently trading at $2.1771, with an overall price swing of 34.5%. The 24-hour trading volume significantly expanded to approximately $25-30 million, surging by 130%-145% compared to before. Open Interest (OI) increased by 18.7%, and the number of trades spiked by over 515%.

Brief Analysis of the Reasons for the Market Movement

• Network Hard Fork Event: The MemeCore network completed a hard fork upgrade, directly driving a 40% price surge within 24 hours to around $2.39, which was the main catalyst.

• Increased Trading Volume and Leverage: Trading volume exceeded $30 million, contract trading numbers +515%, open interest increased, and leveraged funds amplified volatility as they chased the rising price.

Market Views and Outlook

The market sentiment is predominantly optimistic, regarding this movement as a signal for the start of the “Meme 2.0 Super Cycle.” The CoinGecko community is 33% bullish, and analysts predict a potential challenge of the $3 resistance; however, BeInCrypto and others warn of distribution risks, noting that profit-taking is likely after encountering resistance at high levels. X community traders have issued short-term short signals (entry at $2.35-$2.55). Going forward, attention should be paid to whether $2.5 is broken and consolidated—otherwise, short-term correction pressure may increase.

Note: This analysis is automatically generated by AI based on publicly available data and on-chain monitoring, for informational purposes only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"

Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.

华尔街见闻•2026/09/29 01:01

Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business

Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.

华尔街见闻•2026/09/29 00:51

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26